Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind lot-to-lot consistency study of recombinant zoster vaccine (CHO cell) in adults aged 40 years and older
CTR20243851Phase 3Completed
- Sponsor
- MAXVAX Biotechnology
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by MAXVAX Biotechnology. Started Dec 2024; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20243851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243851.